ATE530191T1 - Mntf-peptide und zusammensetzungen und anwendungsverfahren - Google Patents

Mntf-peptide und zusammensetzungen und anwendungsverfahren

Info

Publication number
ATE530191T1
ATE530191T1 AT04704005T AT04704005T ATE530191T1 AT E530191 T1 ATE530191 T1 AT E530191T1 AT 04704005 T AT04704005 T AT 04704005T AT 04704005 T AT04704005 T AT 04704005T AT E530191 T1 ATE530191 T1 AT E530191T1
Authority
AT
Austria
Prior art keywords
compositions
methods
directed
modulating
growth
Prior art date
Application number
AT04704005T
Other languages
English (en)
Inventor
Raymond Ming Wah Chau
Pui-Yuk Dorothy Ko
Original Assignee
Genervon Biopharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genervon Biopharmaceuticals Llc filed Critical Genervon Biopharmaceuticals Llc
Application granted granted Critical
Publication of ATE530191T1 publication Critical patent/ATE530191T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
AT04704005T 2003-01-21 2004-01-21 Mntf-peptide und zusammensetzungen und anwendungsverfahren ATE530191T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44177203P 2003-01-21 2003-01-21
PCT/US2004/001468 WO2004065410A2 (en) 2003-01-21 2004-01-21 Mntf peptides and compositions and methods of use

Publications (1)

Publication Number Publication Date
ATE530191T1 true ATE530191T1 (de) 2011-11-15

Family

ID=32771972

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04704005T ATE530191T1 (de) 2003-01-21 2004-01-21 Mntf-peptide und zusammensetzungen und anwendungsverfahren

Country Status (9)

Country Link
US (2) US7183373B2 (de)
EP (1) EP1587526B1 (de)
JP (3) JP2006516287A (de)
AT (1) ATE530191T1 (de)
AU (1) AU2004205659B2 (de)
CA (1) CA2506855C (de)
DK (1) DK1587526T3 (de)
ES (1) ES2375797T3 (de)
WO (1) WO2004065410A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841531B2 (en) 1996-09-27 2005-01-11 Genervon Biopharmaceuticals Llc Methods and use of motoneuronotrophic factors
DK1587526T3 (da) * 2003-01-21 2012-02-06 Genervon Biopharmaceuticals Llc MNTF-peptider og sammensætninger og anvendelsesmåder
US8986676B2 (en) * 2005-11-10 2015-03-24 Genervon Biopharmaceuticals Llc MNTF differentiation and growth of stem cells
US8340193B2 (en) * 2006-08-04 2012-12-25 Microsoft Corporation Wyner-Ziv and wavelet video coding
CA2669658C (en) * 2006-11-10 2017-12-12 Genervon Biopharmaceuticals Llc Methods of treating neuronal disorders using mntf peptides and analogs thereof
EP2000134A1 (de) * 2007-06-06 2008-12-10 Neuraxo Biopharmaceuticals GmbH Verwendung einer Substanz zur Behandlung von Verletzungen des peripheren Nervensystems
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
WO2009105780A2 (en) * 2008-02-21 2009-08-27 Genervon Biopharmaceuticals Llc Mntf peptide compositions and methods of use
AU2009217269B2 (en) * 2008-02-21 2014-10-02 Dermacare Neuroscience Institute Cosmetic and dermatological formulations of MNTF peptides
WO2016210123A1 (en) 2015-06-26 2016-12-29 Genervon Biopharmaceuticals, LLC Methods of using gm604 in modulating als disease biomarkers leading to prognosis and therapeutic treatment for als disease
US20240261375A1 (en) 2021-05-18 2024-08-08 Ltt Bio-Pharma Co., Ltd. Pharmaceutical composition for treating or preventing disorder associated with administration of anticancer agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309877B1 (en) * 1996-09-27 2001-10-30 Km Biotech, Inc. Polynucleotides encoding motoneuronotrophic factors
US6841531B2 (en) * 1996-09-27 2005-01-11 Genervon Biopharmaceuticals Llc Methods and use of motoneuronotrophic factors
DK1587526T3 (da) * 2003-01-21 2012-02-06 Genervon Biopharmaceuticals Llc MNTF-peptider og sammensætninger og anvendelsesmåder

Also Published As

Publication number Publication date
DK1587526T3 (da) 2012-02-06
US20060052299A1 (en) 2006-03-09
EP1587526A4 (de) 2008-01-02
WO2004065410A3 (en) 2004-12-16
US7795215B2 (en) 2010-09-14
WO2004065410A2 (en) 2004-08-05
US7183373B2 (en) 2007-02-27
US20080125373A1 (en) 2008-05-29
CA2506855C (en) 2013-08-27
AU2004205659B2 (en) 2009-03-26
EP1587526A2 (de) 2005-10-26
CA2506855A1 (en) 2004-08-05
JP2011042659A (ja) 2011-03-03
JP2006516287A (ja) 2006-06-29
ES2375797T3 (es) 2012-03-06
AU2004205659A1 (en) 2004-08-05
JP4913895B2 (ja) 2012-04-11
EP1587526B1 (de) 2011-10-26
JP2012046538A (ja) 2012-03-08

Similar Documents

Publication Publication Date Title
DE60331345D1 (de) Probensubstrat zur biologischen untersuchung
ATE548022T1 (de) Zusammensetzungen mit einer kombination von tetrapeptiden und tripeptiden
ATE551048T1 (de) Proteinhydrolysate enthaltende kosmetische zusammensetzungen
ATE530191T1 (de) Mntf-peptide und zusammensetzungen und anwendungsverfahren
DE69721329D1 (de) Zusammensetzung zur Verzögerung des Haarwuchses und entsprechende Verwendung
AR051512A1 (es) Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3"
WO2004063362A3 (en) Cell cycle progression proteins
NO20060464L (no) Use of CXCL6 chemokine in the prevention or repair of cartilage defects
RS52283B (sr) 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n- metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2- indolinon-monoetansulfonat i njegova primena u farmaceutskoj kompoziciji
DE60322513D1 (de) Stabilisierte TNFR-Fc Formulierung mit Arginin
HUP0100302A2 (hu) Eljárások a szerin/treonin protein-kináz funkció módositására 5-azakinoxalin-vázas vegyületekkel
DE69636365D1 (de) Peptide und zusammensetzungen, die die apoptose modulieren.
BR0214250A (pt) peptìdeos que promovem a aderência, crescimento e secreção da célula
ATE445402T1 (de) Neue verwendung von pde5-hemmern
RU2008117429A (ru) Композиция для обработки волос
ATE411086T1 (de) Verwendung von granulaten in kosmetischen zusammensetzungen auf basis von pyrogenisch hergestelltem siliziumdioxid
IS2631B (is) Aðferðir þar sem integrín-mótlyf eru notuð til að meðhöndla margföld mergæxli og uppsog í bein af völdum mergæxla
BR0016547A (pt) Composição para a modulação e inibição da permeabilidade vascular (vp)
BR0307470A (pt) fração de plasma de um animal hibernante e métodos de purificar uma molécula tendo atividade anti-infarto, de reduzir um infarto em um indivìduo de produzir e de identificar uma molécula anti-infarto e de identificar um inibidor da interação entre a bradicinina e o tipo 2 do receptor de angiotensina ii
BR0108187A (pt) Moléculas trade e usos relacionados com as mesmas
ATE340253T1 (de) Zellkonstrukte erhältlich aus mesenchymalen stammzellen und davon ableitbaren zellen und ihre verwendung
ATE389014T1 (de) Phosphorylierte glyoxalase i und deren verwendung
NO20013795L (no) Regulering av anestesi
DE60314289D1 (de) Synthetische peptidanaloge zur behandlung von krebs
MY143821A (en) Biologically active peptide comprising tyrosyl-seryl-valine (ysv)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1587526

Country of ref document: EP